GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Accounts Payable: ₹5,702 Mil (As of Mar. 2026)


NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
78 GF Score
Price ₹2,438.20
GF Value ₹2,625.78
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Accounts Payable?

GlaxoSmithKline Pharmaceuticals NSE:GLAXO -0.09% 78 Accounts Payable is ₹5,702 Mil as of Mar. 2026. GuruFocus rates NSE:GLAXO with a GF Score™ of 78/100 and a GF Value™ of ₹2,625.78 (Fairly Valued). The stock has 1 warning sign investors should review.

GlaxoSmithKline Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was ₹5,702 Mil.

GlaxoSmithKline Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2025 (₹4,796 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹5,702 Mil).

GlaxoSmithKline Pharmaceuticals's annual Accounts Payable increased from Mar. 2024 (₹6,254 Mil) to Mar. 2025 (₹7,082 Mil) but then declined from Mar. 2025 (₹7,082 Mil) to Mar. 2026 (₹5,702 Mil).

GlaxoSmithKline Pharmaceuticals Accounts Payable Related Terms

GlaxoSmithKline Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Accounts Payable Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,793.27 4,277.89 6,254.10 7,082.49 5,702.21

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,082.49 0.00 4,795.70 0.00 5,702.21
NSE:GLAXO
78GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹5,702 Mil mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Accounts Payable of ₹5,702 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' Accounts Payable too high?
GlaxoSmithKline Pharmaceuticals' current Accounts Payable is ₹5,702 Mil. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Accounts Payable compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' Accounts Payable of ₹5,702 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current Accounts Payable is ₹5,702 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,625.78, compared to a current price of ₹2,438.20 — trading 7.1% below its estimated fair value. The current Accounts Payable is ₹5,702 Mil. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Accounts Payable is ₹5,702 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,438.20 is trading 7.1% below its estimated GF Value™ of ₹2,625.78. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLAXO:

  • Accounts Payable: ₹5,702 Mil
  • GF Value™: ₹2,625.78 vs. price of ₹2,438.20 (7.1% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
78GF Score

Get the complete analysis for NSE:GLAXO

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,438.20
Price
₹2,625.78
GF Value